Cryolife (CRY) Receives Daily Coverage Optimism Score of 0.07

News stories about Cryolife (NYSE:CRY) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cryolife earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave news headlines about the medical equipment provider an impact score of 45.8867661070317 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Shares of Cryolife (CRY) opened at $19.15 on Thursday. Cryolife has a one year low of $14.02 and a one year high of $24.00. The company has a current ratio of 5.96, a quick ratio of 4.90 and a debt-to-equity ratio of 0.29. The company has a market cap of $701.12, a price-to-earnings ratio of 68.39 and a beta of 0.82.

Cryolife (NYSE:CRY) last posted its earnings results on Monday, October 30th. The medical equipment provider reported $0.08 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.08. The company had revenue of $44.00 million during the quarter, compared to the consensus estimate of $44.60 million. Cryolife had a net margin of 5.28% and a return on equity of 6.43%. The firm’s quarterly revenue was down 2.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.13 earnings per share. research analysts predict that Cryolife will post 0.28 EPS for the current fiscal year.

Several research firms have recently commented on CRY. Northland Securities reiterated a “buy” rating and set a $23.50 price objective on shares of Cryolife in a research note on Monday, November 13th. TheStreet downgraded shares of Cryolife from a “b” rating to a “c+” rating in a research note on Monday, October 30th. Zacks Investment Research downgraded shares of Cryolife from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Lake Street Capital lifted their price objective on shares of Cryolife to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, October 11th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $25.00 price objective on shares of Cryolife in a research note on Monday, October 9th. Two analysts have rated the stock with a sell rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $23.63.

In related news, VP David C. Gale sold 20,000 shares of the business’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $19.63, for a total transaction of $392,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director James Benson sold 2,000 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $22.80, for a total transaction of $45,600.00. The disclosure for this sale can be found here. Insiders have sold 61,190 shares of company stock valued at $1,183,840 over the last 90 days. 6.00% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: This news story was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://sportsperspectives.com/2017/12/28/cryolife-cry-receives-daily-coverage-optimism-score-of-0-07.html.

Cryolife Company Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Insider Buying and Selling by Quarter for Cryolife (NYSE:CRY)

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply